Cargando…

Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

BACKGROUND: Few studies have formally assessed whether treatment outcomes have improved substantially over the years for patients with extensive disease small-cell lung cancer (ED-SCLC) enrolled in phase III trials. The objective of the current investigation was to determine the time trends in outco...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oze, Isao, Hotta, Katsuyuki, Kiura, Katsuyuki, Ochi, Nobuaki, Takigawa, Nagio, Fujiwara, Yoshiro, Tabata, Masahiro, Tanimoto, Mitsune
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773043/ https://www.ncbi.nlm.nih.gov/pubmed/19915681 http://dx.doi.org/10.1371/journal.pone.0007835

Ejemplares similares

Treatment-Related Death in Patients with Small-Cell Lung Cancer in Phase III Trials over the Last Two Decades
por: Ochi, Nobuaki, et al.
Publicado: (2012)

Role of Survival Post-Progression in Phase III Trials of Systemic Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2011)

Rapid on-site evaluation with BIOEVALUATOR(®) during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing pulmonary and mediastinal diseases
por: Minami, Daisuke, et al.
Publicado: (2014)

Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
por: Ochi, Nobuaki, et al.
Publicado: (2014)

Endobronchial ultrasound-guided transbronchial needle aspiration of hilar and mediastinal lymph nodes detected on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography
por: Minami, Daisuke, et al.
Publicado: (2016)

Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review
por: Hotta, Katsuyuki, et al.
Publicado: (2015)

Downregulation of TBXAS1 in an iron-induced malignant mesothelioma model
por: Minami, Daisuke, et al.
Publicado: (2015)

Obstructive jaundice at the initial presentation in small-cell lung cancer
por: Ochi, Nobuaki, et al.
Publicado: (2010)

Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
por: Morichika, Daisuke, et al.
Publicado: (2016)

The Role of STAT3 in Non-Small Cell Lung Cancer
por: Harada, Daijiro, et al.
Publicado: (2014)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

A phase I/II trial of weekly nab‐paclitaxel for pretreated non‐small‐cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement
por: Harada, Daijiro, et al.
Publicado: (2019)

Pneumocystis Pneumonia Concomitant with Ectopic ACTH Syndrome Caused by a Large Cell Neuroendocrine Carcinoma of the Thymus
por: Oda, Naohiro, et al.
Publicado: (2017)

Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
por: Yamane, Hiromichi, et al.
Publicado: (2013)

Whole Blood Interferon-Gamma Assay for Baseline Tuberculosis Screening among Japanese Healthcare Students
por: Hotta, Katsuyuki, et al.
Publicado: (2007)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
por: Harada, Daijiro, et al.
Publicado: (2021)

Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
por: Watanabe, Hiromi, et al.
Publicado: (2017)

Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease
por: Oda, Naohiro, et al.
Publicado: (2017)

Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer
por: Ichihara, Eiki, et al.
Publicado: (2018)

A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation
por: Morichika, Daisuke, et al.
Publicado: (2019)

Acute necrotizing encephalopathy in an adult with influenza A infection
por: Ochi, Nobuaki, et al.
Publicado: (2018)

Erythema as a Visual Surrogate Marker of Glucagonoma
por: Ochi, Nobuaki, et al.
Publicado: (2018)

Successful Re-administration of Osimertinib in Osimertinib-induced Interstitial Lung Disease with an Organizing Pneumonia Pattern: A Case Report and Literature Review
por: Itano, Junko, et al.
Publicado: (2019)

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease
por: Okawa, Sachi, et al.
Publicado: (2021)

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan
por: Ando, Eri, et al.
Publicado: (2021)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Dimebon disappointment
por: Jones, Roy W
Publicado: (2010)

The future disappoints
Publicado: (2009)

Disappointments in Surgery
Publicado: (1900)

School for the Disappointed
por: Evans, Mary
Publicado: (1967)

Incredulity and disappointment
por: Cox, M.
Publicado: (2020)

A Disappointment
Publicado: (1888)

Epiphora in lung cancer patients receiving docetaxel: a case series
por: Yamagishi, Tomoko, et al.
Publicado: (2014)

High Uptake of FDG Along a Biliary Stent
por: Nagasaki, Yasunari, et al.
Publicado: (2016)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

Immunomodulatory Effects of Ambroxol on Airway Hyperresponsiveness and Inflammation
por: Takeda, Katsuyuki, et al.
Publicado: (2016)

MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib
por: Ninomiya, Kiichiro, et al.
Publicado: (2018)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
por: Makimoto, Go, et al.
Publicado: (2022)

Demand for weekend outpatient chemotherapy among patients with cancer in Japan
por: Katayama, Hideki, et al.
Publicado: (2020)

Managing Lung Cancer with Comorbid Interstitial Pneumonia
por: Ichihara, Eiki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_huh52tr59adf40ak1belc6r9nn